4 completed, 3 withdrawn, 1 active not recruiting, 1 recruiting. 10 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Withdrawn 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
Follow ImmunoGen, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors IMGC936 - Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | ImmunoGen, Inc. | 56 | 2020-10-29 | 2025-01-15 |
| Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer IMGN853 - Endometrial Cancer | Phase 2 | Recruiting | Alessandro Santin | 50 | 2020-07-15 | 2026-06-26 |
| A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Pembrolizumab, IMGN853 - Endometrial Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 18 | 2020-01-02 | 2026-06-01 |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Mirvetuximab Soravtansine, Bevacizumab - Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | Withdrawn | University of Oklahoma | 2019-05-31 | 2019-06-27 | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer Mirvetuximab soravtansine, Bevacizumab, Carboplatin - Epithelial Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 / Phase 2 | Completed | ImmunoGen, Inc. | 264 | 2016-03-02 | 2024-06-14 |
| An Open-label Phase II Study of Lorvotuzumab Mertansine Lorvotuzumab Mertansine (IMGN901) - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 9 | 2015-05-12 | 2018-08-28 |
| A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer IMGN901, Carboplatin and Etoposide - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | ImmunoGen, Inc. | 181 | 2010-11-01 | 2018-01-18 |
| huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas huC242-DM4 - Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer | Phase 2 | Withdrawn | ImmunoGen, Inc. | 2007-05-01 | 2015-08-26 | |
| Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer BB-10901 - Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | ImmunoGen, Inc. | 64 | 2003-04-01 | 2012-07-18 |
Endometrial Neoplasms (3) · Leukemia, Myeloid, Acute (2) · Small Cell Lung Carcinoma (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Neoplasm Metastasis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Stomach Neoplasms (1)
mirvetuximab soravtansine (4) · lorvotuzumab mertansine (3) · Bevacizumab (2) · Carboplatin (2) · pembrolizumab (2) · Biopsy (1) · CPX-351 (1) · Cytarabine (1) · Daunorubicin (1) · Etoposide (1) · Hydrocortisone (1) · Injections (1) · Liposomes (1) · Methotrexate (1) · Methylprednisolone (1)
United States (9) · Spain (3) · Canada (2) · Belgium (1) · Italy (1) · United Kingdom (1)
Alessandro D. Santin, M.D. (1) · Matthew A Kutny (1) · Naval Daver, MD (1) · Rebecca Porter, MD, PhD (1)
PMID 35511740, PMID 38182653, PMID 40700855
U10CA180886 (1)